Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Vyleesi™, the trade name for Bremelanotide, for the treatment of hypoactive sexual desire disorder (HSDD) is our lead product. A New Drug Application for approval of Vyleesi is pending before the Food and Drug Administration (FDA). We have licensed North American rights to Vyleesi to AMAG Pharmaceuticals, Inc., Chinese rights to Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. and Korean rights to Kwangdong Pharmaceutical Co., Ltd. We have development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis.